Dendritic Cell Cancer Vaccine Market Size, Share, Trends, Industry Analysis Report: By Product, End Use, and Region

Description

List of Tables

The dendritic cell cancer vaccine market size is expected to reach USD 2,285.32 million by 2034, according to a new study by Polaris Market Research. The report "Dendritic Cell Cancer Vaccine Market Size, Share, Trends, Industry Analysis Report: By Product (CreaVax, Sipuleucel-T, and Others), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The dendritic cell cancer vaccine market focuses on immunotherapy treatments that utilize dendritic cells to stimulate the immune system against cancer cells. These vaccines are designed to enhance antigen presentation, leading to a more targeted and sustained immune response against tumors. The market is experiencing growth due to increasing cancer prevalence, advancements in personalized medicine, and rising adoption of immunotherapies.

The dendritic cell cancer vaccine market opportunities lie in expanding clinical research, regulatory approvals, and technological innovations in vaccine manufacturing. Key trends include the integration of dendritic cell vaccines with combination therapies, increased collaborations among pharmaceutical companies, and geographic expansion into emerging markets. As awareness and accessibility improve, the market is expected to continue evolving with a strong focus on innovation and patient-centric treatment approaches.

Dendritic Cell Cancer Vaccine Market Report Highlights

The dendritic cell cancer vaccine market, by product, is segmented into CreaVax, sipuleucel-T, and others. The sipuleucel-T segment dominated the dendritic cell cancer vaccine market share in 2024 due to its ability to enhances the immune response to prostatic acid phosphatase antigen.
The market, by end use, is segmented into pediatrics and adults. The adult segment dominated the market share in 2024. This dominance is attributed to the higher incidence of cancer among adults, leading to increased demand for effective immunotherapeutic interventions.
North America accounted for a major dendritic cell cancer vaccine market revenue share in 2024 due to well-established healthcare infrastructure, significant investments in cancer immunotherapy, and a high prevalence of cancer cases.
A few of the key players in the market are Activartis Biotech GmbH, Batavia Bioservices B.V., DanDrit Biotech, DCPrime, Elios Therapeutics, GlaxoSmithKline plc, ImmunoCellular Therapeutics, Mendus, Northwest Biotherapeutics, and Sanpower Corporation.

Polaris Market Research has segmented the dendritic cell cancer vaccine market report on the basis of product, end use, and region:

By Product Outlook (Revenue - USD Million, 2020-2034)

CreaVax
Sipuleucel-T
Others

By End Use Outlook (Revenue - USD Million, 2020-2034)

Paediatrics
Adults

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM2964

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Dendritic Cell Cancer Vaccine Market Insights

4.1. Dendritic Cell Cancer Vaccine Market - Market Snapshot
4.2. Dendritic Cell Cancer Vaccine Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Advancements in Personalized Immunotherapy
  - 4.2.1.2. Increasing Research and Clinical Trials
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost of Vaccines
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Dendritic Cell Cancer Vaccine Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Dendritic Cell Cancer Vaccine Market, by Product

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
5.3. CreaVax
- 5.3.1. Global Dendritic Cell Cancer Vaccine Market, by CreaVax, by Region, 2020-2034 (USD Million)
5.4. Sipuleucel-T
- 5.4.1. Global Dendritic Cell Cancer Vaccine Market, by Sipuleucel-T, by Region, 2020-2034 (USD Million)
5.5. Others
- 5.5.1. Global Dendritic Cell Cancer Vaccine Market, by Others, by Region, 2020-2034 (USD Million)

6. Global Dendritic Cell Cancer Vaccine Market, by End-Use

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
6.3. Paediatrics
- 6.3.1. Global Dendritic Cell Cancer Vaccine Market, by Paediatrics, by Region, 2020-2034 (USD Million)
6.4. Adults
- 6.4.1. Global Dendritic Cell Cancer Vaccine Market, by Adults, by Region, 2020-2034 (USD Million)

7. Global Dendritic Cell Cancer Vaccine Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Dendritic Cell Cancer Vaccine Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Dendritic Cell Cancer Vaccine Market - North America
- 7.3.1. North America: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
- 7.3.2. North America: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.3.3. Dendritic Cell Cancer Vaccine Market - U.S.
  - 7.3.3.1. U.S.: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.3.4. Dendritic Cell Cancer Vaccine Market - Canada
  - 7.3.4.1. Canada: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
7.4. Dendritic Cell Cancer Vaccine Market - Europe
- 7.4.1. Europe: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
- 7.4.2. Europe: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.3. Dendritic Cell Cancer Vaccine Market - UK
  - 7.4.3.1. UK: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.4. Dendritic Cell Cancer Vaccine Market - France
  - 7.4.4.1. France: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.4.2. France: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.5. Dendritic Cell Cancer Vaccine Market - Germany
  - 7.4.5.1. Germany: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.6. Dendritic Cell Cancer Vaccine Market - Italy
  - 7.4.6.1. Italy: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.7. Dendritic Cell Cancer Vaccine Market - Spain
  - 7.4.7.1. Spain: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.8. Dendritic Cell Cancer Vaccine Market - Netherlands
  - 7.4.8.1. Netherlands: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.9. Dendritic Cell Cancer Vaccine Market - Russia
  - 7.4.9.1. Russia: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.4.10. Dendritic Cell Cancer Vaccine Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
7.5. Dendritic Cell Cancer Vaccine Market - Asia Pacific
- 7.5.1. Asia Pacific: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.3. Dendritic Cell Cancer Vaccine Market - China
  - 7.5.3.1. China: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.3.2. China: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.4. Dendritic Cell Cancer Vaccine Market - India
  - 7.5.4.1. India: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.4.2. India: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.5. Dendritic Cell Cancer Vaccine Market - Malaysia
  - 7.5.5.1. Malaysia: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.6. Dendritic Cell Cancer Vaccine Market - Japan
  - 7.5.6.1. Japan: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.7. Dendritic Cell Cancer Vaccine Market - Indonesia
  - 7.5.7.1. Indonesia: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.8. Dendritic Cell Cancer Vaccine Market - South Korea
  - 7.5.8.1. South Korea: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.9. Dendritic Cell Cancer Vaccine Market - Australia
  - 7.5.9.1. Australia: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.5.10. Dendritic Cell Cancer Vaccine Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
7.6. Dendritic Cell Cancer Vaccine Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.6.3. Dendritic Cell Cancer Vaccine Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.6.4. Dendritic Cell Cancer Vaccine Market - UAE
  - 7.6.4.1. UAE: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.6.5. Dendritic Cell Cancer Vaccine Market - Israel
  - 7.6.5.1. Israel: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.6.6. Dendritic Cell Cancer Vaccine Market - South Africa
  - 7.6.6.1. South Africa: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.6.7. Dendritic Cell Cancer Vaccine Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
7.7. Dendritic Cell Cancer Vaccine Market - Latin America
- 7.7.1. Latin America: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
- 7.7.2. Latin America: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.7.3. Dendritic Cell Cancer Vaccine Market - Mexico
  - 7.7.3.1. Mexico: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.7.4. Dendritic Cell Cancer Vaccine Market - Brazil
  - 7.7.4.1. Brazil: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.7.5. Dendritic Cell Cancer Vaccine Market - Argentina
  - 7.7.5.1. Argentina: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)
- 7.7.6. Dendritic Cell Cancer Vaccine Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Dendritic Cell Cancer Vaccine Market, by Product, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Dendritic Cell Cancer Vaccine Market, by End-Use, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Activartis Biotech GmbH
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Argos Therapeutics, Inc.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Batavia Bioservices B.V.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Bellicum Pharmaceuticals, Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. GlaxoSmithKline plc
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Creagene Inc.
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. DanDrit Biotech USA, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. DCPrime BV
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Dendreon Pharmaceuticals LLC
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Elios Therapeutics, LLC
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development